A cancer drug supplied at ₹2,700 being sold for ₹27,000? That’s not markup; that’s carnage. The court’s proposed fix? A flat 16% retail margin cap on all drugs, essential or not. Sounds simple, but here’s the twist: while small pharmacies and hospital stores might feel the pinch, giants like Sun Pharma are built to weather this storm; thanks to their global specialty drug pipeline and big-ticket acquisitions like Organon. If you’re into pharma stocks, watch this space: the real winners might not be the companies selling medicines to your local chemist, but the ones playing the long game overseas. This isn’t just about pricing; it’s about who controls the future of medicine in India.